Four children diagnosed with one of the deadliest brain cancers known to medicine – a tumor type where fewer than one in a hundred patients survives five years – are alive today with no evidence of disease. Cell therapy for brain cancer produced that result through a method no one had confirmed would work: patient-derived immune cells, drawn from the blood, trained in a lab against three tumor proteins simultaneously, and delivered through a standard IV line into children whose tumors were embedded in the brainstem. The mechanism had been theorized. The sustained clinical outcomes had not been demonstrated in this disease before.
The results come from a first-in-human Phase 1 clinical trial known as ReMIND, led by researchers at Children’s National Hospital in Washington, D.C. The trial enrolled children and young adults with diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system tumors. Phase 1 trials are primarily designed to test safety, not to measure how well a treatment works. The fact that this one produced sustained responses – including patients who remain disease-free years after receiving the therapy – was not something the researchers were expecting.
The findings were published in Nature Medicine in June 2026. They represent a meaningful shift in what researchers believe is possible in cell therapy for brain cancer, a field that has spent decades running into walls. Before understanding what the trial achieved, it helps to understand the problem it was built to solve.
The Scale of the Problem: Why DIPG Has Resisted Treatment for Decades
Brain tumors are now the most common cancer and cause of cancer-related death in children under 15, accounting for approximately 25% of all childhood cancers. Within that already grim category, DIPG occupies the most severe end of the spectrum. It is a rare and aggressive tumor that starts in the pons, the part of the brainstem responsible for breathing and movement. DIPG is challenging to treat because tumor cells diffuse into surrounding brain tissue, making surgical removal impossible.
The median overall survival for newly diagnosed DIPG patients without new therapies is 13.7 months, and the long-term numbers are even more stark. Ninety percent of children diagnosed with DIPG die within two years. The five-year overall survival rate is less than 1%. DIPG accounts for approximately 10 – 15% of pediatric brain tumors overall, meaning roughly 300 children in the United States are diagnosed each year with a cancer that medicine has, until very recently, been almost completely unable to slow.
The treatment record bears that out. Immunotherapies have been shown to work in blood cancers but rarely succeed in solid tumors, especially brain tumors. That immunological blind spot is not incidental. The brain sits behind a highly selective filter called the blood-brain barrier, which blocks most immune cells and drugs from crossing into brain tissue. Treatment is further complicated by the brain’s delicate structure and limited regenerative capacity. While immunotherapy has reshaped adult oncology, its use in pediatric brain tumors remains limited due to an immunosuppressive tumor microenvironment – meaning the environment inside the tumor actively shuts down incoming immune cells.
Diffuse intrinsic pontine glioma is characterized by rapid neurologic decline and markedly limited long-term survival. Tumor location renders surgical removal unsafe, leaving radiotherapy as the primary option for temporary symptom relief. Radiotherapy offers a brief period of neurological improvement in most children but does not alter the ultimate course of the disease. Despite this, it has remained the standard of care for decades, largely because nothing else has worked. According to Catherine Bollard, MBChB, MD, senior vice president and chief research officer at Children’s National and co-senior author of the ReMIND study, “This study represents an important step toward developing safer and more effective T-cell therapies for children with devastating brain cancers.”
How the ReMIND Cell Therapy Brain Cancer Trial Works: Engineering the Patient’s Own Immune Cells
The approach used in ReMIND is categorically different from both chemotherapy and the genetically engineered CAR T-cell therapies that have attracted attention in blood cancers. Dr. Bollard helped develop the tumor-associated antigen T cell (TAA-T) program at Children’s National, which manufactures autologous T cells – drawn from the patient’s own blood – that target tumor-associated proteins. The therapy is multi-antigen, simultaneously targeting three proteins relevant to brain tumors: WT1 (Wilms’ tumor protein), PRAME (preferentially expressed antigen in melanoma), and survivin (BIRC5).
These three proteins are not arbitrary targets. The tumor-associated antigens WT1, PRAME, and survivin are widely expressed by pediatric CNS tumors, and a manufacturing technique has been developed to target these intracellular antigens using autologous, non-genetically engineered T cells. The distinction between this approach and conventional CAR T therapy is important: rather than genetically rewriting the T cells’ targeting code, researchers at Children’s National trained the cells to recognize these proteins through a process of repeated antigen exposure in the lab, preserving a more natural immune response profile.
The ReMIND trial was an open-label, Phase 1 adaptive dose-finding study, designed to determine the safety and feasibility of autologous, systemically administered trivalent T cells targeting WT1, PRAME, and survivin in children with CNS tumors. Eligible patients were divided across three arms: newly diagnosed DIPG patients without lymphodepletion (arm A, with 16 enrolled and 11 infused), and relapsed or recurrent non-brainstem CNS malignancies with or without lymphodepletion (arms B and C).
One of the trial’s most significant design features was its delivery method. Investigators say the results provide early evidence that the patient’s own immune cells, delivered through the bloodstream, can reach and fight tumors in the brain while producing fewer severe side effects than some existing engineered immune therapies. Many other brain tumor immunotherapies require direct injection into the brain or cerebrospinal fluid. Delivering T cells intravenously – through a standard IV line – is far less invasive and avoids the neurological risks associated with intracranial injection, which matters enormously when the tumor is embedded in the brainstem.
Eugene Hwang, MD, chief of Oncology at Children’s National and co-senior author of the study, noted the significance of the combination approach: “We were excited to see that we could preserve safety and quality of life while generating anti-tumor responses by attacking three targets at once.”
Why Triple Targeting Matters
Attacking three tumor proteins simultaneously addresses one of the fundamental reasons that previous therapies for DIPG have failed. The multi-target design may help address tumor heterogeneity, one of the major barriers to successful treatment of aggressive childhood cancers. Tumor heterogeneity means that individual tumors contain cells with slightly different molecular profiles. A therapy targeting a single protein can eliminate cells displaying that protein while leaving others untouched. Cells without the target protein continue to proliferate, and the tumor returns – often more treatment-resistant than before.
By simultaneously targeting WT1, PRAME, and survivin, the ReMIND therapy raises the bar significantly. For a tumor cell to evade the treatment, it would need to lose expression of all three proteins at once, which is biologically far less likely than evading a single-target therapy.
Trial Results: What the Data Shows
The trial results showed that the T cell therapy was well tolerated with low-grade side effects across 33 total patients. None of the dosage levels reached toxicity, and there were only two severe adverse events. For a Phase 1 trial – whose primary job is to identify safety limits – that is a highly favorable profile.
On the efficacy side, the phase 1 trial of multitarget WT1/PRAME/survivin-specific T-cell therapy showed feasibility, defined a maximum tolerated dose, and demonstrated an acceptable safety profile. Systemically infused T cells reached brain tumors, induced anti-tumor responses, and achieved prolonged disease control in some patients, with limited severe toxicities.
The headline finding: the trial produced one complete response and three long-term responders, with some patients remaining disease-free years after treatment – a clinical outcome that has essentially no precedent in DIPG history. “Even in this early-stage trial focused on safety, we were encouraged to see lasting clinical benefit in several patients who otherwise had very few options,” said Dr. Bollard.
The trial also successfully established a feasible manufacturing process, identified a maximum tolerated dose, and defined an early safety profile – key milestones needed to advance the therapy into future Phase 2 studies. These process milestones are not a footnote. Manufacturing autologous (patient-derived) cell therapies at clinical scale is a longstanding bottleneck in the field. Confirming that the process is reproducible and scalable is as important to the therapy’s future as the clinical outcomes themselves.
As a Phase 1 study, ReMIND was designed to test safety and establish dosing parameters across a relatively small cohort. The long-term survival outcomes observed in four patients are clinically meaningful but require confirmation in a larger, controlled Phase 2 trial before they can support broad clinical conclusions. The finding that systemically delivered T cells can reach and act against brain tumors is the core mechanistic proof-of-concept. The survival data is the signal that warrants following it up.
The Broader Context: Where This Fits in Pediatric Oncology
DIPG is estimated to account for approximately 10 – 15% of pediatric brain tumors. According to the National Cancer Institute, approximately 300 children are diagnosed with DIPG in the United States each year. When scaled across the full pediatric brain tumor population, pediatric glioblastoma and related high-grade brain tumors are characterized by aggressive clinical courses and account for significant morbidity and mortality among children.
Nowhere is the unmet need more acute than in pediatric brain tumors. Brain tumors are the most common cancer and leading cause of cancer-related death in children under 15, accounting for approximately 25% of all childhood cancers. The challenge of cracking brain tumor immunotherapy runs deeper than drug design. The brain’s unique immune environment actively suppresses incoming immune cells. Pediatric brain tumors are biologically distinct from adult cancers, often arising during development and presenting diverse histological and molecular profiles. Therapies that perform well in adult oncology or even in adult brain cancer frequently fail when applied to pediatric tumors, partly because the underlying molecular biology differs substantially and partly because treatment toxicity has a proportionally larger impact on a developing nervous system.
The ReMIND trial’s profile on both counts is encouraging. The therapy did not require neurosurgical delivery, avoided the severe toxicity profile seen in some genetically engineered cell therapies, and produced lasting responses in patients with essentially no other viable options.
“Pediatric tumors are one of the greatest challenges in cancer research, with children still facing extremely limited treatment options, and existing treatments often causing severe side effects,” said David Scott, director of Cancer Grand Challenges, which supports the NexTGen team, a group of international collaborators co-led by Dr. Bollard that is taking on the ‘solid tumors in children’ Cancer Grand Challenge.
The NexTGen collaboration represents a structural shift in how this problem is being approached. Rather than isolated institutional trials, international teams are now pooling patient data, manufacturing protocols, and mechanistic insights – a model better suited to rare diseases like DIPG, where no single center sees enough patients to power a large trial independently.
What This Means for You
The ReMIND trial does not yet constitute a proven treatment for DIPG – that determination requires Phase 2 data from a larger patient cohort. What it does establish, definitively, is that cell therapy for brain cancer can work mechanistically in ways that were previously unconfirmed: patient-derived T cells can cross the blood-brain barrier after intravenous delivery, locate tumors embedded in the brainstem, and generate measurable anti-tumor activity – in some cases durable enough to produce long-term survival in a disease where five-year survival has historically been below 1%.
Four children who had no remaining standard treatment options are, by current clinical assessment, disease-free. The therapy that produced those outcomes is now cleared for a Phase 2 study, with a defined manufacturing process and a confirmed safety profile. The multi-target architecture – simultaneously attacking WT1, PRAME, and survivin – addresses the tumor heterogeneity problem that has undermined previous single-target approaches. And the intravenous delivery route removes one of the logistical and safety barriers that have limited the practical deployment of brain tumor immunotherapies.
What to Do Now
Families and clinicians dealing with new or recurrent pediatric brain tumor diagnoses should be aware that the ReMIND trial is now moving forward. The ClinicalTrials.gov registry lists an active follow-on Children’s National immunotherapy study (IMPACT) that is currently recruiting participants. For families navigating a DIPG or relapsed CNS tumor diagnosis today, discussing eligibility for emerging Phase 2 cell therapy trials with a pediatric neuro-oncologist at a major cancer center is a concrete next step.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Scientists Are Experimenting With Immunotherapy to Fight Deadly Artery Plaque